




RealRate

PHARMACEUTICAL 2021

Intec Pharma Ltd
Rank 221 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Intec Pharma Ltd are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intec Pharma Ltd compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Intec Pharma Ltd is the variable Other Net Income, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 252%, being 4.0% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	14,968
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,334
Liabilities, Non-Current	1,029
Other Assets	4,534
Other Compr. Net Income	0
Other Expenses	124
Other Liabilities	0
Other Net Income	-14,004
Other Revenues	0
Property and Equipment	1,394
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	20,896
Liabilities	6,363
Expenses	124
Revenues	0
Stockholders Equity	14,533
Net Income	-14,128
Comprehensive Net Income	-14,128
BaseVar	20,694
ECR before LimitedLiability	129%
Economic Capital Ratio	252%